Terlipressin, also known as triglyceride lysine pressor, is degraded by the corresponding enzymes when it enters the body and finally forms lysine pressor, which is the active substance that exerts its main effect in clinical practice. Its ability to constrict the visceral vessels, especially the small veins in the visceral area, leads to a significant decrease in blood flow, so that a corresponding improvement in hepatic blood flow and portal vein pressure can occur, and therefore it is mainly used clinically for the treatment of ruptured esophagogastric fundic variceal bleeding, and it is generally recommended to be administered 1-2mg every 6 hours in an IV drip. However, the chances of rebleeding are higher in the early stages of drug treatment and sometimes further measures are needed to prevent rebleeding, such as endoscopic sclerotherapy and transendoscopic esophageal variceal ligation. In addition, since terlipressin also has the effect of inducing smooth muscle contraction, it is also used clinically to treat bleeding gastroduodenal ulcers and uterine bleeding from various causes.